drugset / Trial / NCT05426031

Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass

NCT05426031

Phase 4 Completed 130 enrolled University of Miami
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to compare two different dosing strategies of a drug named protamine.

Timeline

Start
2022-06-28
Primary completion
2023-06-01
Completion
2023-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Protamine Sulfate Unknown 1 mg Intravenous
Subject Protamine Sulfate Unknown 250 mg Intravenous